title: Dengue vaccine: come let's fight the menace.
abstract: Although dengue has a global distribution, the World Health Organization (WHO) South-East Asia region together with Western Pacific region bears nearly 75% of the current global disease burden. Globally, the societal burden has been estimated to be approximately 528 to 1300 disability-adjusted life years (DALY) per million to populations in endemic regions Dengue is believed to infect 50 to 100 million people worldwide a year with half a million life-threatening infections requiring hospitalization, resulting in approximately 12,500 to 25,000 deaths. Despite being known for decades and nearly half the world's population is at risk for infection with as many as 100 million cases occurring annually, the pitiable state is that we still have no antiviral drugs to treat it and no vaccines to prevent it. In recent years, however, the development of dengue vaccines has accelerated dramatically in tandem with the burgeoning dengue problem with a rejuvenated vigour. However, recent progress in molecular-based vaccine strategies, as well as a renewed commitment by the World Health Organization (WHO) to co-ordinate global efforts on vaccine development, finally provides hope that control of this serious disease may be at hand. Today, several vaccines are in various stages of advanced development, with clinical trials currently underway on 5 candidate vaccines. Trials in the most advanced stages are showing encouraging preliminary data, and the leading candidate could be licensed as early as 2015.
authors.affiliation: a Department of Community Medicine; MMMC; Solan ; Himachal Pradesh , India.
authors.forename: Sumit
authors.initials: S
authors.lastname: Chawla
authors.forename: Soumya Swaroop
authors.initials: SS
authors.lastname: Sahoo
authors.forename: Inderjeet
authors.initials: I
authors.lastname: Singh
authors.forename: Madhur
authors.initials: M
authors.lastname: Verma
authors.forename: Vikas
authors.initials: V
authors.lastname: Gupta
authors.forename: Sneh
authors.initials: S
authors.lastname: Kumari
mesh_terms: D001210:Asia, Southeastern / Q000453:epidemiology; D002986:Clinical Trials as Topic; D003715:Dengue / Q000453:epidemiology / Q000401:mortality / Q000517:prevention & control*; D053059:Dengue Vaccines / Q000276:immunology* / Q000302:isolation & purification*; D055808:Drug Discovery / Q000639:trends; D014943:Global Health; D006801:Humans; D015994:Incidence; D015995:Prevalence; D016896:Treatment Outcome
chemical_list: D053059:Dengue Vaccines
keywords: Dengue; endemic; tetravalent; trials; vaccine